Read on Twitter
@Pharmdca @semodough @pawcio2009 @PersimmonTI @ripster47 i never thought that $KPTI would trade below 15 after approval in 2nd and 3rd line MM based on BOSTON trial...xpovio already added to the NCCN guidelines...just to give perspective, stock was 25+ when BOSTON trial data
$KPTI was announced...since they already have commercial infrastructure for MM and DLBCL, 2nd and 3rd MM expands 5x number of patients without significant cost increase ...sales in 4th+ line had modest growth because 1) covid19 impact 2) higher toxicity due to twice a week
$KPTI compare to once a week in BOSTON trial and very sick patients 3) takes time for Dr’s to feel comfortable with new treatments as well as company to launch first drug 4) single arm ...sales should be significantly higher in 2021 because 1) stat significant in PFS in
$KPTI randomized trial 2) lower toxicity than 4th line and in comparison to Vd in peripheral Neuropathy 3) Dr’s are familiar with xpovio now 4) 5x patients compare to 4th line MM 5) oral administration 6) covid vaccines should allow patients to visit Dr’s office and hence more
$KPTI number of prescriptions ...dont forget other indications like liposarcoma, endometrosis, GBM etc ...also potential combinations...finally, conservative peak sales would be >1B but EV is <1B...tax selling should be done now...should bounce from jan with JPM conf...
